- Jan 2020: After its Novartis-partnered nonalcoholic steatohepatitis (NASH) drug failed a third midphase trial, Conatus Pharma (CNAT) unveiled a plan to lay off 40% of its staffers. Then the company has found its lifeline—a reverse merger with regenerative medicine player Histogen (HSTO).
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEigLtrJ5YeNQV-TXiD5R5q23jCaVzh_W_4pWul69rVtEhMDyAgqJZ1pp8QX-eA-KeD9dRflg9p0r-nyCI0Xo6kF1cXsEeRYFOSM32yaSDnqix2dFV6EtafyySXFkZXjDnK59E2gImRehko/s1600/CNAT.gif)
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEipFelXom3O2-F_59ubTvicJw5IgQWZCUCWFjQuTOysdwPkh7ZREovOuxE3lfpoalY07DIr3qHiRiYPu-jYrjOi-mShMoC3i0ELIboU7B3vbLZgsdogppUKy3zWaOt4b8LgygQlvks3OsQ/s1600/HSTO-b.jpg)
No comments:
Post a Comment